Valderm ApS is focused on developing valrubicin, a second generation anthracycline, for the innovative once daily topical treatment of hyperproliferative skin diseases such as psoriasis. Preclinical studies have demonstrated the anti-proliferative effect of valrubicin, and it has shown a favorable safety profile in repeated topical applications. Valderm aims to provide a convenient and effective solution for patients suffering from hyperproliferative skin diseases through the development of valrubicin.